Aviado · Research
Longevity Daily
Tuesday, April 28, 2026
Listen
Today's Brief
Today's issue is anchored by early detection: Mount Sinai researchers have developed a blood test that can flag Alzheimer's risk in late midlife, years before symptoms appear — the day's clear must-read. On the supplement science front, NAD+ research is finally graduating from rodent data to rigorous human trials per a sweeping Nature Aging review, and Consumer Reports' independent lab testing of 24 fish oil brands delivers something rare: an actionable quality shortlist. New mouse work pins senescent macrophages as a primary driver of liver aging, a 4-week diet RCT in older adults shows biological age biomarkers shift faster than expected, and Intellia's pause on its Phase 3 CRISPR trials delivers an important safety signal for the gene-editing field.
10 stories2 peer-reviewed1 trials
Cognitive Health & Neuroprotection
A Blood Test Could Spot Alzheimer's Risk Years Before Symptoms Appear
Researchers at the Icahn School of Medicine at Mount Sinai have identified a blood-based biomarker profile capable of detecting elevated Alzheimer's risk during late midlife — giving clinicians a minimally invasive way to flag at-risk adults in their 50s and 60s before cognitive decline begins. This window matters enormously: lifestyle interventions like exercise, sleep optimization, and dietary change carry the strongest evidence base when deployed early, and clinical trials increasingly require pre-symptomatic participants. The study is described as promising and preliminary — large, diverse validation cohorts will be needed before this becomes a routine screening option. Still, for anyone already monitoring their metabolic and cardiovascular health proactively, this is exactly the kind of early-warning tool the field has been working toward for decades.
Read more →Supplements & Compounds
NAD+ Research Is Finally Moving From Mice to Humans — Here's What the Evidence Now Shows
A comprehensive review in Nature Aging marks a turning point for NAD+ supplementation: after more than a decade of compelling but largely animal-model data, the field is now transitioning to rigorous human clinical trials across multiple precursors — NMN, NR, and others — with targeted applications spanning metabolic aging and neurodegeneration. For the millions already taking NAD+ supplements, this is meaningful validation that the science is maturing, but the review is equally clear that definitive human longevity proof remains ahead. The strongest emerging clinical signals are concentrated in specific populations with age-related metabolic dysfunction, not the general healthy adult.
Read more →Consumer Reports Lab-Tested 24 Fish Oil Brands — 16 Passed, Some Didn't
Consumer Reports independently tested 24 fish oil brands for potency, purity, and safety, finding that 16 met all quality and safety standards — a meaningful improvement over their 2012 testing round, when contamination was more prevalent across the category. The report gives supplement buyers something rare in a largely unregulated market: an independent, lab-verified shortlist rather than marketing claims. If fish oil is part of your daily stack, cross-referencing your brand against these findings is one of the most direct quality-assurance moves available to you.
Read more →Research & Papers
Just 4 Weeks of Dietary Change Shifted Biological Age in Older Adults — With Important Caveats
A randomized controlled trial enrolled 104 adults aged 65–75 across four dietary arms for 4 weeks, finding that switching from an omnivorous high-fat diet to either a high-carbohydrate or semi-vegetarian pattern produced measurable reductions in KDM δAge — a composite biomarker-based biological age score. The omnivorous high-carbohydrate group showed the most significant improvement, while the control high-fat group showed no meaningful change. The authors urge caution: these biomarker shifts may reflect acute physiological adaptation to new dietary inputs rather than a true change in aging trajectory, and longer-term studies are required before drawing conclusions about lasting benefit.
Read more →Researchers Screen 10,000 Compounds to Find a New Generation of Senescent Cell Killers
Scientists at Imperial College London screened 10,000 covalent compounds against both senescent and healthy cells, identifying candidates that selectively destroy zombie cells by targeting proteins previously considered undruggable. Unlike existing senolytics such as quercetin and dasatinib, covalent inhibitors form permanent bonds with their protein targets — potentially delivering more potent and durable senolytic activity. This is early-stage drug discovery, but expanding the chemical toolkit for senolysis is an important step toward clinical candidates with better selectivity and tolerability profiles.
Read more →Senescent Macrophages Are a Key Driver of Liver Aging — and Senolytics Reverse It in Mice
New mouse research identifies senescent macrophages in liver tissue as a primary source of the chronic sterile inflammation driving age-related liver dysfunction and the metabolic liver disease that can progress to fibrosis and cancer. Clearing these specific senescent cells with senolytic therapy significantly reduced liver inflammation and restored liver function in aged mice. Mouse-stage caveat applies, but the study adds important mechanistic precision to which senescent cell populations matter most — a critical step toward targeted senolytics rather than blunt whole-body approaches.
Read more →Lifestyle & Nutrition
A Measured Look at Fasting for Longevity: What the Evidence Actually Supports Right Now
A perspective in Biogerontology offers one of the more balanced assessments of fasting to date, concluding that a trial of intermittent fasting or time-restricted eating is reasonable for motivated overweight or obese adults — but that current evidence does not justify population-wide adoption or confident longevity claims in humans. The authors flag key contraindications — frailty, osteopenia, and a history of eating disorders — as reasons to proceed cautiously or avoid fasting protocols altogether. Their roadmap for the human studies still needed, including mechanistic and multi-omics endpoints, is worth reading for anyone tracking the fasting-mimetic drug space.
Read more →Does Air Pollution Actually Accelerate Biological Aging? The Answer Is More Nuanced Than Expected
While chronic air pollution exposure is well-established as a mortality and disease risk, new analysis questions whether it constitutes genuine accelerated aging — i.e., whether it registers on epigenetic clocks and composite biological age measures — or primarily causes harm through other pathways. The distinction matters for how we model environmental risk and whether air quality interventions (purifiers, relocation, masking) deserve explicit status as longevity tools. The practical takeaway is the same regardless: minimizing long-term fine particulate matter exposure remains one of the most underrated environmental levers for healthspan.
Read more →Industry & Policy
Intellia Pauses Phase 3 CRISPR Trials for Amyloidosis After Serious Liver Adverse Event
Intellia Therapeutics has placed both Phase 3 trials of its CRISPR gene-editing therapy nexiguran ziclumeran (nex-z) on hold after a patient in the MAGNITUDE trial experienced a Grade 4 liver adverse event — a serious safety signal for a field moving quickly toward in vivo gene editing in patients. The paused trials were targeting transthyretin amyloidosis (ATTR), a progressive protein-misfolding disease affecting the heart and peripheral nerves that is increasingly relevant to longevity medicine. This pause is a reminder that the in vivo safety profile of CRISPR-based therapies remains a major unresolved challenge, even as efficacy data continues to generate enthusiasm.
Read more →The Regulatory Loophole That Could Pull NMN — and Other Supplements — Off Shelves
The Council for Responsible Nutrition (CRN) is rallying industry stakeholders around reform of DSHEA's drug preclusion clause — the provision that bars a compound from being sold as a supplement once it enters the pharmaceutical drug approval pipeline, a rule that previously threatened the legal status of NMN. Speaking at SupplySide Connect, the CRN's general counsel called for industry alignment and legislative action to close this gap before it stifles innovation and removes evidence-backed ingredients from consumer access. This is a slow-moving regulatory fight, but its outcome will directly determine which longevity-relevant compounds remain legally available on supplement shelves in the U.S.
Read more →